A woman with metastatic triple-negative breast cancer that had failed surgery, chemo, and radiation saw nearly 79% tumor shrinkage with a combination of immunotherapy, radiation, GM-CSF, and thymosin alpha-1.
79% tumor shrinkagein a triple-negative breast cancer patient who had failed all standard treatments, after adding thymosin alpha-1 to immunotherapy
What the researchers found
The combination of PD-1 inhibitor, SBRT, GM-CSF, and thymosin alpha-1 produced a 78.97% regression in the target lesion and 56.73% regression in non-irradiated observed lesions (abscopal effect) in a patient with treatment-resistant mTNBC.
Why it matters
Triple-negative breast cancer with metastases has very few effective treatment options. This case demonstrates that combining immune-boosting peptides like thymosin alpha-1 with immunotherapy and targeted radiation may overcome treatment resistance, especially through abscopal effects on distant tumors.
The numbers in context
48-year-old female patient who had not responded to multiple lines of therapy including surgery, chemotherapy, and radiotherapy.
How the study worked
Single case report from a clinical trial combining stereotactic body radiotherapy (SBRT), PD-1 inhibitor immunotherapy, GM-CSF, and thymosin alpha-1. Response assessed using RECIST v1.1 criteria after 2 treatment cycles.
Who was studied
48-year-old female with metastatic triple-negative breast cancer resistant to multiple prior therapies
What this study cannot tell us
Single case report — the weakest form of clinical evidence. One dramatic response does not prove the regimen works for other patients. No control group, blinding, or statistical analysis possible. The clinical trial is ongoing and broader results are needed.
How to read the evidence
Preliminary evidence: single case report from a clinical trial. While the response is dramatic, case reports cannot establish treatment efficacy — larger trials are essential.
When this study was published
Published in 2024. Reports on a recent clinical trial combination regimen.
The bigger picture
Immunotherapy alone often fails in triple-negative breast cancer. Adding immune modulators like thymosin alpha-1 and GM-CSF alongside focused radiation may prime the immune system more effectively, producing responses in patients who have run out of standard options. The abscopal effect — where untreated tumors also shrink — suggests the combination created a systemic immune response against the cancer.
Questions still open
- Will these results hold up in a larger controlled trial with more mTNBC patients?
- Which component of the four-drug combination is most critical for the abscopal effect?
- How long will this treatment response last, and will the cancer eventually develop resistance?
Common questions
What is thymosin alpha-1 and how does it help fight cancer?
What is an abscopal effect?
Read the original research
PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.
Medicine, 103(34), e39271
Citation
Yu, Jiamin; Wang, Qiang; Wang, Lijun; Zong, Dan; He, Xia. (2024). PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.. Medicine, 103(34), e39271. https://doi.org/10.1097/MD.0000000000039271